<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04692298</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-20-430</org_study_id>
    <nct_id>NCT04692298</nct_id>
  </id_info>
  <brief_title>Effects od Pulse Consumption on Bone Health of Postmenopausal Women</brief_title>
  <official_title>Pulse Consumption Improves Gut Health, Metabolic Outcomes, and Bone Biomarkers of Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oklahoma State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>USDA Beltsville Human Nutrition Research Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Oklahoma State University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effects of the addition of 100 grams/day of cooked pulses&#xD;
      (i.e. lentil, pinto beans, peas, chickpeas, kidney beans) to the diet of postmenopausal women&#xD;
      for 12 weeks on gut health, metabolic outcomes and bone biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With approximately 1.3 million women reaching menopause each year in the US and about&#xD;
      one-third of a woman's life is spent in this state, it is imperative to identify effective,&#xD;
      safe, and economical approaches that can minimize disease risk that is associated with this&#xD;
      phase of life. Pulses are excellent source of fiber, protein, essential amino acids,&#xD;
      vitamins, minerals and phytochemicals, that can act as prebiotics and prevent gut dysbiosis&#xD;
      and promote a healthy gut. A few studies in overweight or obese adults have shown the health&#xD;
      benefits of pulses, including gut modulating potential. However, studies examining the use of&#xD;
      pulse crops are limited, especially in alleviating health risks associated with menopause.&#xD;
      The objective of this study is to evaluate the prebiotic potential of pulse-based diet and&#xD;
      consequent effects on metabolic and bone biomarkers in postmenopausal women. We hypothesize&#xD;
      that daily intake of pulses, due to its nutrient content and many other bioactive compounds&#xD;
      including fiber content, will beneficially affect gut health and subsequently improve&#xD;
      metabolic outcomes and bone markers in postmenopausal women. To accomplish our objectives, 40&#xD;
      postmenopausal women (50- 65 y old and â‰¥ 1 y menopause) will be recruited and will be asked&#xD;
      to consume 100 g/d of pulse (alternate between lentils, pinto beans, peas, chickpeas, and&#xD;
      kidney beans) for 3 months. Pulse intake, anthropometric measures, markers of gut and bone&#xD;
      health, and metabolic outcomes will be assessed at baseline and at the end of pulse&#xD;
      consumption.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fecal bacteria</measure>
    <time_frame>change from baseline after 90 days</time_frame>
    <description>analyzed by 16sRNA sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fecal short chain fatty acid</measure>
    <time_frame>change from baseline after 90 days</time_frame>
    <description>analyzed by gas chromatography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fecal immunoglobulin A</measure>
    <time_frame>change from baseline after 90 days</time_frame>
    <description>analyzed by enzyme-linked immunoassay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma concentrations of fatty acid binding protein</measure>
    <time_frame>change from baseline after 90 days</time_frame>
    <description>analyzed by enzyme-linked immunoassay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting blood glucose</measure>
    <time_frame>change from baseline after 90 days</time_frame>
    <description>analyzed using clinical chemistry analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood glycosylated hemoglobin</measure>
    <time_frame>change from baseline after 90 days</time_frame>
    <description>analyzed using clinical chemistry analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood insulin</measure>
    <time_frame>change from baseline after 90 days</time_frame>
    <description>analyzed using enzyme linked immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood C-peptide</measure>
    <time_frame>change from baseline after 90 days</time_frame>
    <description>analyzed using enzyme linked immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood total cholesterol</measure>
    <time_frame>change from baseline after 90 days</time_frame>
    <description>analyzed using clinical chemistry analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood HDL cholesterol</measure>
    <time_frame>change from baseline after 90 days</time_frame>
    <description>analyzed using clinical chemistry analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood LDL cholesterol</measure>
    <time_frame>change from baseline after 90 days</time_frame>
    <description>analyzed using clinical chemistry analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood triglycerides</measure>
    <time_frame>change from baseline after 90 days</time_frame>
    <description>analyzed using clinical chemistry analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood C-terminal telopeptide of type 1 collagen (CTX)</measure>
    <time_frame>change from baseline after 90 days</time_frame>
    <description>analyzed by enzyme-linked immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood procollagen type 1 N-propeptide (P1NP)</measure>
    <time_frame>change from baseline after 90 days</time_frame>
    <description>analyzed by enzyme-linked immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone density</measure>
    <time_frame>at baseline</time_frame>
    <description>assessed by dual energy xray absorptiometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Pulse</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will consume kidney beans, lentil, pinto beans, black-eyed pea, chickpea</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pulses</intervention_name>
    <description>kidney beans, pinto beans, lentil, black-eyed pea and chickpea</description>
    <arm_group_label>Pulse</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1 year without menstrual cycle&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any medication use (for the past 6 m) that affects glucose, lipids, bone and&#xD;
             inflammation markers, dietary supplements, and non-steroidal anti-inflammatory&#xD;
             medications&#xD;
&#xD;
          -  allergy to pulse crops&#xD;
&#xD;
          -  tobacco use&#xD;
&#xD;
          -  excessive alcohol intake&#xD;
&#xD;
          -  antibiotic use&#xD;
&#xD;
          -  major surgery within 6 m of study enrollment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postmenopausal women</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EDRALIN A LUCAS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EDRALIN A LUCAS, PhD</last_name>
    <phone>4057443132</phone>
    <email>edralin.a.lucas@okstate.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sam Emerson, PhD</last_name>
    <phone>4057442303</phone>
    <email>edralin.a.lucas@okstate.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nutritional Sciences Department, Oklahoma State University</name>
      <address>
        <city>Stillwater</city>
        <state>Oklahoma</state>
        <zip>74078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edralin Lucas, PhD</last_name>
      <phone>405-744-3132</phone>
      <email>edrali.a.lucas@okstate.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sam Emerson, PhD</last_name>
      <phone>(405)744-2303</phone>
      <email>sam.emerson@okstate.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oklahoma State University</investigator_affiliation>
    <investigator_full_name>Edralin Lucas</investigator_full_name>
    <investigator_title>Jim an Lynn Williams Professor</investigator_title>
  </responsible_party>
  <keyword>bone health</keyword>
  <keyword>pulses</keyword>
  <keyword>microbiome</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

